Contineum Therapeutics (CTNM) Assets Average (2024 - 2026)

Contineum Therapeutics' Assets Average history runs 3 years deep, the most recent figure standing at $269.0 million for Q1 2026.

• In Q1 2026, Assets Average rose 30.86% year-over-year to $269.0 million; the TTM figure through Mar 2026 stood at $269.0 million (up 30.86% YoY), while the FY2025 annual figure was $244.7 million, up 42.61% from the prior year.
• Assets Average was $269.0 million for Q1 2026 at Contineum Therapeutics, up from $233.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $269.0 million in Q1 2026 to a low of $127.0 million in Q1 2024.
• Historically, Assets Average has averaged $202.0 million across 3 years, with a median of $205.6 million in 2025.
• Biggest YoY gain for Assets Average was 61.89% in 2025; the steepest drop was 14.55% in 2025.
• A 3-year view of Assets Average shows it stood at $214.4 million in 2024, then grew by 9.0% to $233.7 million in 2025, then gained by 15.08% to $269.0 million in 2026.
• The last three Assets Average figures came in at $269.0 million (Q1 2026), $233.7 million (Q4 2025), and $186.9 million (Q3 2025), per Business Quant data.